European Commission revokes marketing authorisation for Novartis’ crizanlizumab
European Pharmaceutical Review
AUGUST 11, 2023
Crizanlizumab is a once-a-month, humanised monoclonal antibody infusion, indicated for the prevention of recurrent vaso‑occlusive crises (pain crises) in sickle cell disease patients aged 16 years and above. However, the STAND results did not suggest new safety concerns with crizanlizumab.
Let's personalize your content